UDCA for Gallstone Dissolution: Mechanism, Dosage & Clinical Evidence

Ursodeoxycholic acid (UDCA) provides a non-surgical treatment option for selected patients with cholesterol gallstones. This article reviews the evidence base for UDCA gallstone dissolution therapy, covering the mechanism of action, dosing protocols, patient selection criteria, expected outcomes, and the important clinical considerations that determine treatment success or failure.

Cholesterol Gallstones and the Rationale for UDCA Therapy

Cholesterol gallstones form when bile becomes supersaturated with cholesterol relative to bile acids and phospholipids, exceeding the solubilizing capacity of mixed micelles. Approximately 80% of gallstones in Western populations are cholesterol-rich (containing >50% cholesterol by weight). While laparoscopic cholecystectomy is the standard treatment for symptomatic gallstone disease, up to 30% of patients are either unwilling to undergo surgery or have contraindications related to comorbidities, advanced age, or anesthetic risk. For these patients, and for individuals with small, asymptomatic cholesterol stones electing to avoid surgery, oral UDCA dissolution therapy is a recognized pharmacotherapeutic option.

How UDCA Dissolves Cholesterol Gallstones

UDCA dissolves cholesterol gallstones through three complementary biochemical effects. First, it reduces biliary cholesterol secretion by inhibiting intestinal cholesterol absorption and decreasing hepatic cholesterol synthesis via downregulation of HMG-CoA reductase. Second, UDCA enriches the bile acid pool, replacing up to 40–50% of endogenous bile acids, which increases the cholesterol-solubilizing capacity of bile. Third, UDCA promotes the formation of liquid crystalline phases at the stone surface, a physical-chemical process in which cholesterol molecules are extracted from the gallstone surface into the aqueous bile environment. This process occurs gradually and requires sustained, continuous dosing over months.

Importantly, UDCA does not dissolve calcified or pigment (bilirubin) stones because these are not composed of cholesterol. Pre-treatment imaging to determine stone composition is therefore essential. Calcification, visible on plain radiography or CT, is an absolute contraindication to dissolution therapy.

Dosing Protocol and Administration

The standard UDCA dose for gallstone dissolution is 8–10 mg/kg/day. For a 70 kg patient, this translates to 560–700 mg/day. The total daily dose may be administered as a single bedtime dose, which takes advantage of the overnight period of gallbladder stasis when bile cholesterol saturation is highest, or divided into two or three doses. Bedtime dosing is more effective than morning dosing because it coincides with the diurnal peak of biliary cholesterol saturation.

Treatment duration ranges from 6 to 24 months, depending on stone characteristics. Therapy should continue for at least 3 months after sonographic confirmation of dissolution because microscopic cholesterol crystals may persist even after stones are no longer visible on ultrasound. The typical UDCA capsule or tablet strength is 150 mg, 250 mg, or 300 mg. The prescribing physician calculates the dose based on actual body weight.

UDCA therapy for gallstone dissolution is generally well tolerated. The most common adverse event is mild diarrhea, reported in 2–5% of patients, which is usually self-limiting and manageable by temporary dose adjustment. Unlike chenodeoxycholic acid, UDCA does not cause hepatotoxicity or hypertransaminasemia at therapeutic doses.

Patient Selection Criteria

Successful UDCA dissolution therapy depends on rigorous patient selection. The following criteria determine treatment candidacy:

• Stone composition: Radiolucent (cholesterol-rich) stones confirmed by oral cholecystography or CT. Calcified stones or stones with a calcified rim on CT will not dissolve.
• Stone size: Ideally <20 mm diameter. Multiple small stones (<5 mm each) dissolve faster and more completely than a single large stone. Stones 5–10 mm have intermediate dissolution rates.
• Gallbladder function: A functioning gallbladder with a patent cystic duct, confirmed by oral cholecystography or HIDA scan. A non-functioning gallbladder cannot deliver UDCA-enriched bile to the stones.
• Stone number: Multiple small stones have higher dissolution rates than a single large stone. Floating stones (those with density less than bile) are particularly amenable to dissolution.
• Symptoms: Mild or moderate biliary symptoms. Patients with severe biliary colic, acute cholecystitis, biliary pancreatitis, or common bile duct stones should be managed surgically.
• Patient compliance: Continuous daily dosing is essential. Interrupted therapy leads to re-supersaturation of bile and cessation of dissolution.

Clinical Efficacy and Dissolution Rates

In carefully selected patients, complete gallstone dissolution is achieved in 30–60% of patients over 6–24 months of continuous UDCA therapy. The wide range reflects differences in patient selection, stone characteristics, and dosing adherence across clinical studies. Key efficacy data from the literature include:

• Small stones (<5 mm): Complete dissolution in 60–90% of patients within 6–12 months.
• Medium stones (5–10 mm): Complete dissolution in 40–60% over 12–18 months.
• Large stones (10–20 mm): Complete dissolution in 20–40% over 18–24 months.
• Floating stones: Higher dissolution rates than non-floating stones of the same size, presumably reflecting higher cholesterol content and lower density.
• Combination therapy: UDCA combined with chenodeoxycholic acid (CDCA), each at 5–7.5 mg/kg/day, can improve dissolution rates for certain stone types by achieving more rapid bile cholesterol desaturation. However, the hepatotoxicity risk associated with CDCA and the availability of UDCA as monotherapy has made combination therapy less commonly used in current practice.

Recurrence After Discontinuation

Gallstone recurrence after successful dissolution is a significant clinical limitation of UDCA therapy. Approximately 25–30% of patients develop recurrent stones within 2 years of discontinuing treatment, rising to approximately 50% at 5 years. This occurs because UDCA treatment corrects the biochemical abnormality during therapy but does not address the underlying metabolic predisposition to cholesterol-saturated bile. Once UDCA is stopped, bile cholesterol saturation returns to pre-treatment levels in most patients, and the lithogenic process resumes.

Post-dissolution surveillance with periodic ultrasound is recommended, with typical follow-up intervals of 6–12 months. Some clinicians maintain patients on low-dose UDCA (4–5 mg/kg/day) as maintenance therapy after dissolution, though this practice varies and is not supported by evidence from large randomized controlled trials. Recurrent stones are typically of similar composition to the original stones and may respond to a second course of UDCA dissolution.

UDCA vs Chenodeoxycholic Acid (CDCA)

Chenodeoxycholic acid (CDCA), the 7α-epimer of UDCA, was the first oral bile acid approved for gallstone dissolution and was introduced in the 1970s. UDCA subsequently replaced CDCA as the preferred agent in most markets. The key clinical advantages of UDCA over CDCA are:

Related Resources